Trading a PROK straddle lets you take a pure volatility position on ProKidney Corp without committing to a direction. ProKidney Corp's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate PROK straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on PROK profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when ProKidney Corp stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the PROK straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the PROK straddle is the cleanest expression of that view. Our scanner prices every PROK straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a PROK straddle into a catalyst or short a PROK straddle to harvest decay, the options straddle setups that matter are all in one place.
